ADMA Biologics Soars 11.62% on FDA Approval for Yield Boost

ADMA Biologics' stock surged 11.62% in pre-market trading on April 28, 2025, driven by significant regulatory developments.

ADMA Biologics, the first U.S. plasma producer, has secured groundbreaking FDA approval for a 20% yield boost technology. This approval is expected to accelerate revenue growth by the end of 2025. The innovative production yield enhancement process highlights ADMA's efficient internal R&D engine, which spans production and regulatory compliance.

This approval marks a significant milestone for ADMA Biologics, positioning the company as a leader in plasma production technology. The enhanced yield process is anticipated to improve operational efficiency and drive future growth, making ADMA Biologics a key player in the biotechnology sector.